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lation had risk factors associated with cardiovascular events. No
signiﬁcant difference (P = 0.6945) was found in the proportion
of subjects using aspirin among the non-selective NSAID,
naproxen, and cox-II cohorts, with 46.8%, 48.8%, and 49.4%,
respectively. Likewise, no signiﬁcant differences were found
among the treatment cohorts with respect to: strength, frequency,
and duration of aspirin use (P = 0.3840, P = 0.8088 and P =
0.6838, respectively). Finally, no signiﬁcant difference (P =
0.2778) was found in the proportion of subjects using aspirin
among those with risk factors for cardiovascular events versus
those without. CONCLUSIONS: Unexpectedly, these results
indicate that aspirin utilization, strength, frequency, and dura-
tion are independent of both subjects’ cardiovascular risk proﬁle
(i.e. risk vs. no risk) and the NSAID class utilized (i.e. selective
vs. nonselective).
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OBJECTIVE: Randomized, controlled trials (RCT’s) are consid-
ered to be the gold standard of scientiﬁc evidence to assess safety
and effectiveness of cardiovascular devices. However, RCT use
is challenging to implement in certain device trials, due to logis-
tical and ethical reasons. The FDA understands that assessment
of device technologies must balance the competing demands of
maximizing scientiﬁc validity against the practical realities of
performing (and effectively completing) these clinical studies.
Hence, non-randomized clinical trials are sometimes used in
device evaluation. Propensity score analysis, as an alternative to
traditional covariate adjustment methods, has been increasing in
popularity as a technique to control for baseline differences
between treatment groups in non-randomized cardiovascular
device studies. METHODS: Propensity scores provide a conve-
nient methodology for covariate adjustment when multiple
covariates are involved. However, propensity score methodology
does not eliminate many of the scientiﬁc limitations of non-
randomized studies compared to RCT’s, and should not be
viewed as a substitute for performing a randomized study. In
using propensity score modeling, a full pre-speciﬁcation of
covariates to be included and the model to be used is recom-
mended to minimize the concern of bias introduced by post hoc
model development. RESULTS: Furthermore, sensitivity analy-
sis should be performed to demonstrate the robustness of study
outcome in the face of hidden bias due to unmeasured or
unquantiﬁable covariates. Lastly, it is recommended that con-
ventional covariate adjustment as well as propensity score
adjustment should be performed to demonstrate consistency of
outcomes between techniques. CONCLUSION: Propensity score
methodology has increased in popularity for covariate adjust-
ment in non-randomized cardiovascular device studies. However,
there are limitations to this methodology, which must be fully
appreciated to avoid erroneous inferences from study data. 
Randomized trials are still preferred and strongly encouraged
whenever possible, especially for the evaluation of novel cardio-
vascular devices.
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OBJECTIVES: The Eplerenone Post-Acute Myocardial Infarc-
tion Heart Failure Efﬁcacy and Survival Study (EPHESUS)
showed that the addition of eplerenone to optimal medical
therapy reduced both morbidity and mortality in patients with
acute myocardial infarction (AMI) complicated by left ventricu-
lar dysfunction and heart failure whilst reducing the number and
duration of heart failure re-hospitalisations. A budget impact
model was developed to estimate the effects of adding eplerenone
to standard care in the UK National Health Service (NHS).
METHODS: Within the model the efﬁcacy of eplerenone is
based on the EPHESUS study. This is applied to UK epidemio-
logical data on the incidence of AMI, proportion of survivors
developing heart failure and their prognosis. UK drug acquisi-
tion costs and NHS hospital inpatient costs and average length
of stay for England are included. All costs are expressed in
pounds sterling. The model estimates the incremental costs and
beneﬁts of adding eplerenone to standard care in heart failure
resulting from AMI from the perspective of NHS health care
decision makers over a three-year period. Input variables include
population, incidence of AMI and annual rate of eplerenone
uptake. RESULTS: If all eligible patients are treated in an NHS
Primary Care Trust of population 250,000, the estimated cost
per life year saved is 6,701 pounds in year three, for an addi-
tional expenditure of £256,959. This level of treatment results
in a reduction of 101 bed days for re-hospitalisations due to
heart failure, at a cost per bed day avoided of €1207. CON-
CLUSIONS: With hospital inpatient care the biggest single
health care cost in heart failure, reduction in hospitalisation is a
key priority within the UK NHS. Models such as the one
described here enable the economic consequences of using a new
drug to be identiﬁed and clarify the role of drug treatment in
delivering NHS priorities.
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OBJECTIVES: To estimate incremental cost-effectiveness of
adding a GPIIb/IIIa inhibitor (eptiﬁbatide) to percutaneous coro-
nary intervention (PCI) and standard medical management
(MM) versus PCI + MM alone in Poland for patients with non-
ST-elevation myocardial infarction (NSTEMI) at high risk of
recurrent ischemia or cardiovascular death. METHODS: A
Markov model was constructed to estimate the additional costs
and beneﬁts of a GPIIb/IIIa inhibitor on top of standard care.
The model has 4 disease states (no event, post-ischemia, post-
MI, death) and two tunnel states (refractory ischemia, non-fatal
MI). PCI + MM include beta blockers, ACE inhibitors, aspirin,
heparin and clopidogrel. The model takes the Polish national
health payer perspective and runs for the expected lifetime of the
patient. The effectiveness parameters were taken from a 6-month
GPIIb/IIIa clinical trial and extrapolated to 45 years with an esti-
mated Weibull function. Event and follow-up costs are based on
assumed treatment patterns. The results of the model were
expressed in total (discounted) costs and life years per patient,
and incremental cost per life year gained. A series of one-way
sensitivity analyses has been conducted on the major model
inputs. RESULTS: The lifetime discounted costs for the base case
analysis are 13,856 PLN per patient for the PCI + MM group
and 15,570 PLN for the eptiﬁbatide group (a difference of 1714
PLN). The use of eptiﬁbatide provides an additional average of
0.05 year of life per patient compared with PCI + MM. The
incremental cost effectiveness ratio for the lifetime model, with
